- Eiger BioPharmaceuticals Inc EIGR announced the publication of data from the investigator-sponsored Phase 3 TOGETHER study in patients with COVID-19 in the New England Journal of Medicine.
- The data exhibited that among predominantly vaccinated participants with COVID-19, a single-dose treatment with Eiger's investigational agent, peginterferon lambda, resulted in significantly decreased clinical events.
- The primary endpoint was a composite endpoint of COVID-19-related hospitalization or emergency room visits greater than six hours.
- Secondary endpoints included SARS-CoV-2 viral clearance, all-cause hospitalization, mortality due to COVID-19, days in the hospital and on a ventilator, and adverse events.
- In the study, 931 patients received peginterferon lambda, and 1,018 received a placebo.
- The publication detailed results, highlighting a 51% reduction in the risk of hospitalization or emergency room visits (primary endpoint) with peginterferon lambda.
- Lambda reduced the risk of hospitalization by 42% and COVID-19-related death by 50%
- Related: Eiger BioPharma Shuns Plans For FDA Emergency Use Nod For COVID-19 Treatment.
- The risk of COVID-19 hospitalization or all-cause death was reduced by 47% in participants receiving peginterferon lambda.
- In patients receiving treatment within three days of symptom onset, greater treatment effects were observed in the peginterferon lambda group, including a 65% reduction of COVID-19-related hospitalization, 81% risk reduction in all-cause death, and 89% risk reduction among unvaccinated patients.
- Price Action: EIGR shares are up 39.9% at $2.85 on the last check Thursday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
